Literature DB >> 11329134

Met protein and hepatocyte growth factor (HGF) in papillary carcinoma of the thyroid: evidence for a pathogenetic role in tumourigenesis.

L P Ruco1, A Stoppacciaro, F Ballarini, M Prat, S Scarpino.   

Abstract

In the last 10 years, evidence has accumulated that overexpression of Met protein is a distinguishing feature of almost every case of well-differentiated papillary carcinoma. Increased expression of the protein is probably due to enhanced transcription of the MET gene and/or to post-transcriptional mechanisms. So far, alterations of the MET gene have not been recognized, but evidence has been provided that activated RAS and RET can cause accumulation of MET RNA. Thus, the possibility exists that dysregulation of MET is the final result of different molecular pathways capable of inducing thyroid cell transformation; RET rearrangements might account for some of the cases, but the demonstration that the majority of papillary carcinomas do not have recognized alterations of the RET gene strongly suggests that MET gene dysregulation can also be achieved through other molecular pathways. Dysregulation of MET causes marked accumulation of Met protein in tumour cells that is promptly detected by immunohistochemistry. Thus, overexpression of Met protein might represent an immunohistochemical marker of papillary carcinoma, potentially helpful in problematic cases, but caution is required; moderate expression of Met protein is observed in non-neoplastic thyroid diseases, such as Graves' and Hashimoto's thyroiditis, and reagents active on paraffin sections may have a low affinity and/or low specificity for Met protein, leading to artifactual staining. Met protein-positive papillary carcinoma cells may produce hepatocyte growth factor (HGF) and may activate HGF through the urokinase-type plasminogen activator (uPA) bound to urokinase-type plasminogen activator receptor (uPA-R). Thus, papillary carcinoma cells possess the molecular machinery necessary for a productive HGF/Met interaction. In vitro studies have demonstrated that HGF enhances the motility and invasiveness of tumour cells and induces the synthesis and release of chemokines active in the recruitment of dendritic cells. These observations provide a rational basis for the understanding of two distinguishing features of papillary carcinoma. First, the tumour is often characterized by early metastatic spread to regional lymph nodes and by multifocal involvement of the gland, which suggests highly invasive behaviour. Second, a prominent peritumoural inflammatory reaction is often observed, which suggests cross-talk between tumour cells and the immune system. Copyright 2001 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11329134     DOI: 10.1002/path.847

Source DB:  PubMed          Journal:  J Pathol        ISSN: 0022-3417            Impact factor:   7.996


  10 in total

1.  Induction of a proinflammatory program in normal human thyrocytes by the RET/PTC1 oncogene.

Authors:  Maria Grazia Borrello; Luisella Alberti; Andrew Fischer; Debora Degl'innocenti; Cristina Ferrario; Manuela Gariboldi; Federica Marchesi; Paola Allavena; Angela Greco; Paola Collini; Silvana Pilotti; Giuliana Cassinelli; Paola Bressan; Laura Fugazzola; Alberto Mantovani; Marco A Pierotti
Journal:  Proc Natl Acad Sci U S A       Date:  2005-10-03       Impact factor: 11.205

2.  c-Met inhibitor synergizes with tumor necrosis factor-related apoptosis-induced ligand to induce papillary thyroid carcinoma cell death.

Authors:  Rong Bu; Shahab Uddin; Maqbool Ahmed; Azhar R Hussain; Saif Alsobhi; Tarek Amin; Abdurahman Al-Nuaim; Fouad Al-Dayel; Jehad Abubaker; Prashant Bavi; Khawla S Al-Kuraya
Journal:  Mol Med       Date:  2012-03-27       Impact factor: 6.354

3.  Expression of serine peptidase inhibitor Kunitz type 1 in differentiated thyroid cancer.

Authors:  Chien-Liang Liu; Po-Sheng Yang; Ming-Nan Chien; Yuan-Ching Chang; Chi-Hsin Lin; Shih-Ping Cheng
Journal:  Histochem Cell Biol       Date:  2018-03-12       Impact factor: 4.304

4.  MicroRNA signature distinguishes the degree of aggressiveness of papillary thyroid carcinoma.

Authors:  Linwah Yip; Lindsey Kelly; Yongli Shuai; Michaele J Armstrong; Yuri E Nikiforov; Sally E Carty; Marina N Nikiforova
Journal:  Ann Surg Oncol       Date:  2011-05-03       Impact factor: 5.344

5.  RET/PTC1-driven neoplastic transformation and proinvasive phenotype of human thyrocytes involve Met induction and beta-catenin nuclear translocation.

Authors:  Giuliana Cassinelli; Enrica Favini; Debora Degl'Innocenti; Alessandro Salvi; Giuseppina De Petro; Marco A Pierotti; Franco Zunino; Maria Grazia Borrello; Cinzia Lanzi
Journal:  Neoplasia       Date:  2009-01       Impact factor: 5.715

6.  A multi-gene approach to differentiate papillary thyroid carcinoma from benign lesions: gene selection using support vector machines with bootstrapping.

Authors:  Krzysztof Fujarewicz; Michal Jarzab; Markus Eszlinger; Knut Krohn; Ralf Paschke; Małgorzata Oczko-Wojciechowska; Małgorzata Wiench; Aleksandra Kukulska; Barbara Jarzab; Andrzej Swierniak
Journal:  Endocr Relat Cancer       Date:  2007-09       Impact factor: 5.678

7.  Large needle aspiration biopsy and galectin-3 determination in selected thyroid nodules with indeterminate FNA-cytology.

Authors:  A Carpi; A G Naccarato; G Iervasi; A Nicolini; G Bevilacqua; P Viacava; P Collecchi; L Lavra; C Marchetti; S Sciacchitano; A Bartolazzi
Journal:  Br J Cancer       Date:  2006-06-27       Impact factor: 7.640

8.  Serum concentrations of HGF and IL-8 in patients with active Graves' orbitopathy before and after methylprednisolone therapy.

Authors:  M Nowak; L Siemińska; J Karpe; B Marek; B Kos-Kudła; D Kajdaniuk
Journal:  J Endocrinol Invest       Date:  2015-06-11       Impact factor: 4.256

9.  Intraoperative MET-receptor targeted fluorescent imaging and spectroscopy for lymph node detection in papillary thyroid cancer: novel diagnostic tools for more selective central lymph node compartment dissection.

Authors:  Pascal K C Jonker; Madelon J H Metman; Luc H J Sondorp; Mark S Sywak; Anthony J Gill; Liesbeth Jansen; Thera P Links; Paul J van Diest; Tessa M van Ginhoven; Clemens W G M Löwik; Anh H Nguyen; Robert P Coppes; Dominic J Robinson; Gooitzen M van Dam; Bettien M van Hemel; Rudolf S N Fehrmann; Schelto Kruijff
Journal:  Eur J Nucl Med Mol Imaging       Date:  2022-04-07       Impact factor: 10.057

10.  Detection and molecular characterisation of thyroid cancer precursor lesions in a specific subset of Hashimoto's thyroiditis.

Authors:  A Gasbarri; S Sciacchitano; A Marasco; M Papotti; A Di Napoli; A Marzullo; P Yushkov; L Ruco; A Bartolazzi
Journal:  Br J Cancer       Date:  2004-09-13       Impact factor: 7.640

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.